MedTrace Logo

Deworming Against Tuberculosis

NCT00857116 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2013-08-29

No results posted yet for this study

Summary

The purpose of this study is to investigate whether treatment against intestinal helminths in patients with pulmonary tuberculosis undergoing chemotherapy could improve the clinical outcome by enhancing host immunity.

Conditions

Interventions

DRUG

Albendazole

Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis

DRUG

Placebo

Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis

Sponsors & Collaborators

  • University of Gondar

    collaborator OTHER

  • Armauer Hansen Research Institute, Ethiopia

    collaborator OTHER

  • Linkoeping University

    lead OTHER_GOV

Principal Investigators

  • Ebba Abate, MSc · University of Gondar and Linkoeping University

  • Ermias Diro, MD · University of Gondar

  • Thomas Schoen, MD PhD · Linkoeping University, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2013-06-30
Completion
2013-08-31

Countries

  • Ethiopia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857116 on ClinicalTrials.gov